Cargando…
Efficacy of trabectedin in metastatic solitary fibrous tumor
Solitary fibrous tumor is a rare tumor type and has an unpredictable course. Local recurrence rate varies between 9 and 19%, and rate of metastatic involvement between 0 and 36 %. It is characterized by a typical architecture and immuno-histochemistry tests. The most important prognostic factor is t...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PAGEPress Publications
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3208416/ https://www.ncbi.nlm.nih.gov/pubmed/22066036 http://dx.doi.org/10.4081/rt.2011.e29 |
_version_ | 1782215612732276736 |
---|---|
author | Chaigneau, Loïc Kalbacher, Elsa Thiery-Vuillemin, Antoine Fagnoni-Legat, Christine Isambert, Nicolas Aherfi, Lionel Pauchot, Julien Delroeux, Delphine Servagi-Vernat, Stephanie Mansi, Laura Pivot, Xavier |
author_facet | Chaigneau, Loïc Kalbacher, Elsa Thiery-Vuillemin, Antoine Fagnoni-Legat, Christine Isambert, Nicolas Aherfi, Lionel Pauchot, Julien Delroeux, Delphine Servagi-Vernat, Stephanie Mansi, Laura Pivot, Xavier |
author_sort | Chaigneau, Loïc |
collection | PubMed |
description | Solitary fibrous tumor is a rare tumor type and has an unpredictable course. Local recurrence rate varies between 9 and 19%, and rate of metastatic involvement between 0 and 36 %. It is characterized by a typical architecture and immuno-histochemistry tests. The most important prognostic factor is the complete resection of primary tumor. Treatment of recurrences is not clearly established. If a solitary fibrous tumor is too advanced to allow surgical resection, radiotherapy and chemotherapy may be used. The most often used drugs are doxorubicine and\or ifosfamide. We report the case of man with metastatic solitary fibrous tumor treated with trabectedin, administered at a dose of 1.5 mg/m² every 3 weeks. After 3 cycles, metastases had significantly decreased. Recurrence of the disease was demonstrated 8 months after the start of trabectedin. This case shows that trabectedin is a possible treatment option. |
format | Online Article Text |
id | pubmed-3208416 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | PAGEPress Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-32084162011-11-07 Efficacy of trabectedin in metastatic solitary fibrous tumor Chaigneau, Loïc Kalbacher, Elsa Thiery-Vuillemin, Antoine Fagnoni-Legat, Christine Isambert, Nicolas Aherfi, Lionel Pauchot, Julien Delroeux, Delphine Servagi-Vernat, Stephanie Mansi, Laura Pivot, Xavier Rare Tumors Case Report Solitary fibrous tumor is a rare tumor type and has an unpredictable course. Local recurrence rate varies between 9 and 19%, and rate of metastatic involvement between 0 and 36 %. It is characterized by a typical architecture and immuno-histochemistry tests. The most important prognostic factor is the complete resection of primary tumor. Treatment of recurrences is not clearly established. If a solitary fibrous tumor is too advanced to allow surgical resection, radiotherapy and chemotherapy may be used. The most often used drugs are doxorubicine and\or ifosfamide. We report the case of man with metastatic solitary fibrous tumor treated with trabectedin, administered at a dose of 1.5 mg/m² every 3 weeks. After 3 cycles, metastases had significantly decreased. Recurrence of the disease was demonstrated 8 months after the start of trabectedin. This case shows that trabectedin is a possible treatment option. PAGEPress Publications 2011-07-18 /pmc/articles/PMC3208416/ /pubmed/22066036 http://dx.doi.org/10.4081/rt.2011.e29 Text en ©Copyright L. Chaigneau et al., 2011 This work is licensed under a Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0). Licensee PAGEPress, Italy |
spellingShingle | Case Report Chaigneau, Loïc Kalbacher, Elsa Thiery-Vuillemin, Antoine Fagnoni-Legat, Christine Isambert, Nicolas Aherfi, Lionel Pauchot, Julien Delroeux, Delphine Servagi-Vernat, Stephanie Mansi, Laura Pivot, Xavier Efficacy of trabectedin in metastatic solitary fibrous tumor |
title | Efficacy of trabectedin in metastatic solitary fibrous tumor |
title_full | Efficacy of trabectedin in metastatic solitary fibrous tumor |
title_fullStr | Efficacy of trabectedin in metastatic solitary fibrous tumor |
title_full_unstemmed | Efficacy of trabectedin in metastatic solitary fibrous tumor |
title_short | Efficacy of trabectedin in metastatic solitary fibrous tumor |
title_sort | efficacy of trabectedin in metastatic solitary fibrous tumor |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3208416/ https://www.ncbi.nlm.nih.gov/pubmed/22066036 http://dx.doi.org/10.4081/rt.2011.e29 |
work_keys_str_mv | AT chaigneauloic efficacyoftrabectedininmetastaticsolitaryfibroustumor AT kalbacherelsa efficacyoftrabectedininmetastaticsolitaryfibroustumor AT thieryvuilleminantoine efficacyoftrabectedininmetastaticsolitaryfibroustumor AT fagnonilegatchristine efficacyoftrabectedininmetastaticsolitaryfibroustumor AT isambertnicolas efficacyoftrabectedininmetastaticsolitaryfibroustumor AT aherfilionel efficacyoftrabectedininmetastaticsolitaryfibroustumor AT pauchotjulien efficacyoftrabectedininmetastaticsolitaryfibroustumor AT delroeuxdelphine efficacyoftrabectedininmetastaticsolitaryfibroustumor AT servagivernatstephanie efficacyoftrabectedininmetastaticsolitaryfibroustumor AT mansilaura efficacyoftrabectedininmetastaticsolitaryfibroustumor AT pivotxavier efficacyoftrabectedininmetastaticsolitaryfibroustumor |